Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide

Abstract

Abstract Purpose The purpose of this study was to determine the safety, feasibility, and immunologic responses of treating grade 4 astrocytomas with multiple infusions of anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed T cells (EGFR BATs) in combination with radiation and chemotherapy. Methods This phase I study used a 3 + 3 dose escalation design to test the safety and feasibility of intravenously infused EGFR BATs in combination with radiation and temozolomide (TMZ) in patients with newly diagnosed grade 4 astrocytomas (AG4). After finding the feasible dose, an expansion cohort with unmethylated O 6 -methylguanine-DNA methyltransferase (MGMT) tumors received weekly EGFR BATs without TMZ. Results The highest feasible dose was 80 × 10 9 EGFR BATs without dose-limiting toxicities (DLTs) in seven patients. We could not escalate the dose because of the limited T-cell expansion. There were no DLTs in the additional cohort of three patients with unmethylated MGMT tumors who received eight weekly infusions of EGFR BATs without TMZ. EGFR BATs infusions induced increases in glioma specific anti-tumor cytotoxicity by peripheral blood mononuclear cells ( p < 0.03) and NK cell activity ( p < 0.002) ex vivo, and increased serum concentrations of IFN-γ ( p < 0.03), IL-2 ( p < 0.007), and GM-CSF ( p < 0.009). Conclusion Targeting AG4 with EGFR BATs at the maximum feasible dose of 80 × 10 9 , with or without TMZ was safe and induced significant anti-tumor-specific immune responses. These results support further clinical trials to examine the efficacy of this adoptive cell therapy in patients with MGMT-unmethylated GBM. ClinicalTrials.gov Identifier : NCT03344250

Topics & Concepts